查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
COVID-19 緩解產品全球市場2022-2029
市場調查報告書
商品編碼
1140748

COVID-19 緩解產品全球市場2022-2029

Global COVID-19 Mitigation Products Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

FDA 舉措的增加將推動市場增長。

隨著 COVID-19 緊急情況的加劇，FDA 正在採取一些積極措施來接觸供應鏈中的其他人，包括醫療設備製造商、醫院和團購組織。 FDA 已與全球 1,000 多個設備製造基地建立聯繫，重點關注虛擬設備和服務。外展活動將主要關注兩種類型的虛擬設備：由於 COVID-19 大流行的爆發而需求量很大的設備，例如 PPE 和呼吸機，以及如果供應中斷可能會出現短缺的設備。你給了它。 FDA 已授權一些沒有 NIOSH（美國國家職業安全與健康研究所）許可的進口一次性呼吸器供醫護人員使用，並已發布 EUA 以增加過濾式面罩呼吸器的供應。因此，由於加大了對醫療設備和服務普及的努力和戰略，預計在預測期內市場將在全球範圍內擴張。

地理滲透。

北美將是預測期內的主要地區。

據估計，在預測期內，北美地區將佔據全球 COVID-19 緩解產品的最大市場份額。美國每10萬人的冠狀病毒死亡率低於一些歐洲國家。到2022年，美國醫療保健支出將達到3.3萬億美元，佔全球醫療保健支出的42%以上。到 2020 年 3 月，國會批准了一項史無前例的 2.2 萬億美元 COVID-19 主要救助計劃。這包括弗吉尼亞州、疾病預防控制中心、FDA、醫療保險、國家戰略儲備和 1610 億美元的 COVID-19 疫苗。醫院雇主協會報告的每月 500 億美元的赤字不包括在內。 2020 年 8 月，CDC 開發了兩項實驗室測試來識別導致 COVID-19 的病毒 SARS-CoV-2。更新的這些測試也被用於測試甲型和乙型流感病毒。同時檢測三種病毒將為公共衛生官員提供減少這些病毒在其社區中傳播並保護稀缺資源所需的資訊。

拉丁美洲已成為全球 COVID-19 疫苗試驗的主要地點，該病毒在社區中的廣泛存在使開發人員能夠測試疫苗功效。墨西哥還有來自法國賽諾菲、美國製藥巨頭強生和兩家中國公司的後期臨床試驗。

競爭格局。

COVID-19 緩解產品具有很強的競爭力，包括多個主要和新興市場參與者。全球 COVID-19 緩解產品市場包括3M Company、Abbott、Sanofi、Pfizer、Eli Lilly、Merck、3Scan、Advenio Technosys、Amara Health Analytics、Avalon等公司。主要參與者採用了多種增長戰略，例如產品發布、臨床試驗、收購和合作夥伴關係，為 COVID-19 緩解產品的全球增長做出了貢獻。例如，2020 年 1 月，Nihon Kohden 推出了 NKV-550 系列呼吸機系統，該系統提供了新生兒到成人重症監護環境所需的一整套應用。它是一款配備觸摸面板並配備直觀用戶界面和屏幕幫助功能的呼吸機。 2020 年 4 月 2 日，生物技術領導者 Cresta International 推出了 Cresta Instant Hand Hygiene Solution，這是一種先進的手部消毒配方。這種革命性的產品提供即時 99.9% 的細菌保護，具有抗菌和防腐特性，使其成為全方位保護和清新的快速解決方案。 2020 年 3 月，再生元和賽諾菲還對多達 400 名患者的非處方關節炎藥物 Kevzara（sarilumab）進行了評估，用於治療嚴重的 COVID-19 冠狀病毒感染，並在美國啟動了 II/III 期臨床項目。

全球 COVID-19 緩解產品市場報告將提供對大約 120 個市場數據表、131 個圖表和 170 頁的訪問權限

內容

第 1 章調查方法及範圍

  • 調查方法
  • 市場範圍

第 2 章主要趨勢和發展

第 3 章執行摘要

  • 按診斷產品和服務劃分的市場細分
  • 按重症監護產品和服務劃分的市場細分
  • 醫療 ICT 市場細分
  • 按製藥行業產品劃分的市場細分
  • 個人和防護裝備市場細分
  • 與 COVID-19 相關的製造工廠的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
    • 抑制因素
    • 商機
  • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 價值鏈分析
  • 專利分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措

第 7 章診斷設備和服務

  • 血清學檢測試劑盒
  • 機器人 PCR 系統和軟件
  • PCR 儀器和軟件
  • 鼻腔和口腔拭子
  • PCR 試劑和耗材
  • 自採集PCR檢測試劑盒
  • X射線檢測設備
  • 其他

第 8 章重症監護產品和服務

  • 有創呼吸機
  • 無創呼吸機
  • 便攜式呼吸機
  • 下一代呼吸機
  • 腎透析
  • 激增能力醫院/ICU
  • 體外膜氧合器
  • 其他

第 9 章醫療 ICT 領域

  • E健康
  • 人工智能、大數據、深度學習
  • 區塊鏈技術
  • 地理空間監測系統服務
  • 家庭醫療IT
  • 其他

第 10 章製藥行業的副產品

  • 疫苗
  • 治療藥
  • 其他

第 11 章個人和防護裝備

  • 醫用手套
  • 醫用口罩
  • 醫用 PPE 長袍
  • 洗手液/表面消毒劑
  • 醫用面罩
  • PPE 滅菌系統和耗材
  • 醫療眼保健
  • 其他

第 12 章 COVID-19 相關製造工廠

  • 呼吸機
  • 血清學檢測試劑盒
  • 自取PCR檢測試劑盒
  • PCR試劑
  • PCR系統
  • 手套
  • PPE 防護服
  • 其他

第 13 章最終用戶

  • 醫院
  • 緊急醫療服務 (EMS)
  • 實驗室
  • 研究所
  • 家庭護理和療養院
  • 診所
  • 其他

第 14 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 15 章競爭格局

  • 競爭場景
  • 競爭對手戰略分析
  • 市場情況/份額分析
  • 併購分析

第 16 章公司簡介

  • 3M Company
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Abbott
  • Agilent Technologies
  • Medtronic
  • Pfizer
  • Qualaris Healthcare Solutions
  • Allscripts Healthcare Solutions
  • Agfa Healthcare
  • AbCellera
  • 3Scan
  • Sanofi
  • Advenio Technosys
  • Siemens
  • Amara Health Analytics
  • Regeneron Pharmaceuticals
  • Avalon
  • Eli Lilly
  • Merck
  • Koninklijke Philips NV

第17章 DataM

簡介目錄
Product Code: DMPH2606

Market Overview

COVID-19 Mitigation Products Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Mitigation products reduce the risk of contamination and slow the spread of COVID-19. The COVID-19 global pandemic has increased the demand for essential mitigation products and services. COVID-19 has put pressure on MedTech and the pharmaceutical industry, with high demand for diagnostic tests, vaccines, ventilators, personal protective equipment (PPE), and other essential medical supplies. The global COVID-19 mitigation market is growing due to several factors such as rising demand for COVID-19 vaccine, growing awareness towards protection from COVID-19 globally, and rising government and non-government organization's initiatives to meet the global demand for diagnostics, protection, and other products related to COVID-19.

Market Dynamics: Increase in FDA initiative drives market growth.

With high COVID-19 emergencies, the FDA has taken several proactive steps to contact medical device manufacturers and others in the supply chain, including hospitals and group purchasing organizations. The FDA has reached over 1,000 device manufacturing sites globally, focusing on virtual devices and services. The outreach has focused on two main types of virtual devices: those that are in high demand due to the COVID-19 pandemic outbreak, such as PPE and ventilators, and devices that may be prone to a potential shortage if there is a supply disruption. The FDA issued a EUA to increase the supply of filtering facepiece respirators by authorizing certain imported disposable respirators that are not the National Institute for Occupational Safety and Health (NIOSH)-approved for use by health care professionals. Hence, with increasing such efforts and strategies to increase the availability of devices and services, the market is expected to grow over the forecast period worldwide.

Market Segmentation: The ventilator segment is projected to be the dominant segment in the market during the forecast period.

The COVID-19 Related Manufacturing Plant segmented as Ventilators, Serologic Test Kits, Self-collection PCR Test Kits, PCR Reagents, PCR Systems, Gloves, PPE Gowns and others.

Advancements in mechanical ventilators aimed to provide improved services, settle on better choices, and improve patient comfort alongside the blending of pathophysiology, medicine, and engineering to enhance the quality of medical care in respiratory distresses. To meet rising demand worldwide, all ventilator manufacturers are ramping up their production, analyzing the criticality of the situation; even other companies, such as various leading US-based car manufacturing companies, are also considering manufacturing ventilators by teaming up with ventilator manufacturing companies to set up as many units as much as possible. It is estimated that in April 2020 that over 900,000 ventilators were in demand worldwide, with a shortage of 80,000 in the U.S. alone. Major companies that provide the U.S. with the devices include General Electric Co., Medtronic PLC, Hill-Rom Holdings Inc., ResMed Inc., and Sweden's Getinge AB are adopting various strategies to meet the rising demand. For instance, in the first three months of 2020, Dragerwerk AG & Co. KGaA saw a sharp rise, increasing by 116.7%. In the medical division, orders rose by 177.2%, driven primarily by demand for ventilators. On March 30th, 2020, Smiths Group contracted with the U.K. Government for a significant ramp-up in producing its life-saving Smiths Medical paraPAC plus™ ventilators. Production is expected to grow rapidly, increasing from hundreds a month to thousands a month to fulfill 10,000 units in response to the U.K. Government's challenge to U.K. technology and engineering businesses to help save lives in the coronavirus pandemic.

In pharma industry products segment, vaccine sub segment held significant share in the market.

The pharma industry is expected to grow significantly over the forecast period due to ongoing clinical trials for the COVID-19 vaccine. In August 2020, about 172 economies were engaged in discussions to participate in COVAX, a global initiative to work with vaccine manufacturers to provide countries with equal access to safe and effective vaccines when licensed and approved. COVAX has the largest and most diverse COVID-19 vaccine portfolio globally, including nine candidate vaccines, with a further nine under evaluation and conversations underway with other major producers. COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO), in partnership with developed and developing country vaccine manufacturers. It is the only worldwide initiative working with governments and manufacturers to ensure that COVID-19 vaccines are available globally to higher- and lower-income countries.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American region is estimated to dominate the global COVID-19 mitigation products accounting for the largest market share over the forecast period. The rate of coronavirus deaths per 100,000 people in the U.S. is lower than in several European countries. By 2022, U.S. healthcare spending stood at $3.3 trillion, more than 42% of global healthcare expenditures. By March 2020, Congress approved an unprecedented $2.2 trillion COVID-19 first relief package. It includes $161 Billion to the VA, CDC, FDA, Medicare, the Strategic National Stockpile, and COVID-19 Vaccines. It does not cover the $50 billion monthly deficit reported by the Hospitals Managers Association. In August 2020, CDC developed two laboratory tests identifying SARS-CoV-2, the virus that causes COVID-19. The newer of these tests are also used to test for influenza A and B viruses. Testing for all three viruses simultaneously will provide public health officials with the information they need to help reduce the spread of these viruses in the community while conserving resources in short supply.

Latin America has become a prime location for global COVID-19 vaccine trials, with widespread viruses in the community allowing developers to test their vaccines' efficiency. Mexico also carries out late-stage trials for France's Sanofi, U.S. pharmaceutical giant Johnson & Johnson, and two Chinese companies.

Competitive Landscape:

The COVID-19 mitigation products are highly competitive and consist of several major and new market players. Some of the global COVID-19 mitigation products markets are 3M Company, Abbott, Sanofi, Pfizer, Eli Lilly, Merck, 3Scan, Advenio Technosys, Amara Health Analytics, and Avalon, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, contributing to the growth of the COVID-19 Mitigation Products globally. For instance, On January 2020, Nihon Kohden debuted its NKV-550 Series Ventilator System, which offers a full suite of applications necessary in a critical care setting for neonates through adults. The ventilator features an integrated touchscreen, an intuitive user interface, and on-screen help functions. On April 2nd, 2020, Clensta International, a leading biotechnology company, launched the Clensta Instant Hand Hygiene Solution, advanced formula for hand sanitization. The novel product offers instant 99.9% germ protection with antimicrobial and antiseptic properties, establishing the new product as a quick solution for all-around protection and freshness. Also, In March 2020, Regeneron Pharmaceuticals and Sanofi launched a Phase II/III clinical program in the U.S. evaluating the marketed arthritis drug Kevzara (sarilumab) as a severe treatment for COVID-19 coronavirus infection in up to 400 patients.

The global COVID-19 mitigation products market report would provide an access to approximately 120 market data tables, 131 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Diagnostic Products and Services
  • 3.2. Market Snippet by Intensive Care Products & Services
  • 3.3. Market Snippet by Medical ICT
  • 3.4. Market Snippet by Pharma Industry Products
  • 3.5. Market Snippet by Personal & Protection Gear
  • 3.6. Market Snippet by COVID-19 Related Manufacturing Plant
  • 3.7. Market Snippet by End-User
  • 3.8. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Diagnostic Products and Services

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnostic Products and Services Segment
    • 7.1.2. Market attractiveness index, By Diagnostic Products and Services Segment
  • 7.2. Serologic Test Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Robotic PCR Systems & Software
  • 7.4. PCR Instrumentation & Software
  • 7.5. Nose & Mouth Swabs
  • 7.6. PCR Reagents & Consumables
  • 7.7. Self-collection PCR Test Kits
  • 7.8. X-Ray Procedures
  • 7.9. Others

8. By Intensive Care Products & Services

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Intensive Care Products & Services Segment
    • 8.1.2. Market attractiveness index, By Intensive Care Products & Services Segment
  • 8.2. Invasive Mechanical Ventilators *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Noninvasive Ventilators
  • 8.4. Portable Ventilators
  • 8.5. Next Generation Ventilators
  • 8.6. Kidney Dialysis
  • 8.7. Surge Capacity Hospitals & ICUs
  • 8.8. Extracorporeal Membrane Oxygenation Procedures
  • 8.9. Others

9. By Medical ICT

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Medical ICT Segment
    • 9.1.2. Market attractiveness index, By Medical ICT Segment
  • 9.2. E-Health *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. AI, Big Data & Deep Learning
  • 9.4. Blockchain Technologies
  • 9.5. Geo-Surveillance Systems & Services
  • 9.6. Homecare IT
  • 9.7. Others

10. By Pharma Industry Products

  • 10.1. Introduction
    • 10.1.1. Market size analysis, and y-o-y growth analysis (%), By Pharma Industry Products Segment
    • 10.1.2. Market attractiveness index, By Pharma Industry Products Segment
  • 10.2. Vaccines*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 10.3. Therapeutic Drugs
  • 10.4. Others

11. By Personal & Protection Gear

  • 11.1. Introduction
    • 11.1.1. Market size analysis, and y-o-y growth analysis (%), By Personal & Protection Gear Segment
    • 11.1.2. Market attractiveness index, By Personal & Protection Gear Segment
  • 11.2. Medical Gloves *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 11.3. Medical Face Masks
  • 11.4. Medical PPE Gowns
  • 11.5. Hand & Surface Sanitizers
  • 11.6. Medical Face Shields
  • 11.7. PPE Sterilization: Systems & Consumables
  • 11.8. Medical Eye Protection
  • 11.9. Others

12. By COVID-19 Related Manufacturing Plant

  • 12.1. Introduction
    • 12.1.1. Market size analysis, and y-o-y growth analysis (%), By COVID-19 Related Manufacturing Plant Segment
    • 12.1.2. Market attractiveness index, By COVID-19 Related Manufacturing Plant Segment
  • 12.2. Ventilators*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 12.3. Serologic Test Kits
  • 12.4. Self-collection PCR Test Kits
  • 12.5. PCR Reagents
  • 12.6. PCR Systems
  • 12.7. Gloves
  • 12.8. PPE Gowns
  • 12.9. Others

13. By End-User

  • 13.1. Introduction
    • 13.1.1. Market size analysis, and y-o-y growth analysis (%), By End-User Segment
    • 13.1.2. Market attractiveness index, By End-User Segment
  • 13.2. Hospitals*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 13.3. Emergency Medical Services (EMS)
  • 13.4. Clinical Labs
  • 13.5. Research Bodies
  • 13.6. Homecare & Nursing Homes
  • 13.7. Clinics
  • 13.8. Others

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key region-specific dynamics
    • 14.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.2.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.2.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.2.10.1. U.S.
      • 14.2.10.2. Canada
      • 14.2.10.3. Mexico
  • 14.3. South America
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.3.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.3.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.3.10.1. Brazil
      • 14.3.10.2. Argentina
      • 14.3.10.3. Rest of South America
  • 14.4. Europe
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.4.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.4.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.4.10.1. Germany
      • 14.4.10.2. U.K.
      • 14.4.10.3. France
      • 14.4.10.4. Spain
      • 14.4.10.5. Italy
      • 14.4.10.6. Rest of Europe
  • 14.5. Asia Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.5.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.5.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.5.10.1. China
      • 14.5.10.2. India
      • 14.5.10.3. Japan
      • 14.5.10.4. Australia
      • 14.5.10.5. Rest of Asia Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.6.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

15. Competitive Landscape

  • 15.1. Competitive scenario
  • 15.2. Competitor strategy analysis
  • 15.3. Market positioning/share analysis
  • 15.4. Mergers and acquisitions analysis

16. Company Profiles

  • 16.1. 3M Company*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio and Description
    • 16.1.3. Key Highlights
    • 16.1.4. Financial Overview
  • 16.2. Abbott
  • 16.3. Agilent Technologies
  • 16.4. Medtronic
  • 16.5. Pfizer
  • 16.6. Qualaris Healthcare Solutions
  • 16.7. Allscripts Healthcare Solutions
  • 16.8. Agfa Healthcare
  • 16.9. AbCellera
  • 16.10. 3Scan
  • 16.11. Sanofi
  • 16.12. Advenio Technosys
  • 16.13. Siemens
  • 16.14. Amara Health Analytics
  • 16.15. Regeneron Pharmaceuticals
  • 16.16. Avalon
  • 16.17. Eli Lilly
  • 16.18. Merck
  • 16.19. Koninklijke Philips NV
  • List not Exhaustive*

17. DataM

  • 17.1. Appendix
  • 17.2. About us and services
  • 17.3. Contact us